SRCircumventing imatinib resistance

Michael W N Deininger, Brian Druker

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.

Original languageEnglish (US)
Pages (from-to)108-110
Number of pages3
JournalCancer Cell
Volume6
Issue number2
DOIs
StatePublished - Aug 2004

Fingerprint

Clinical Trials
Recurrence
Mutation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genes
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

SRCircumventing imatinib resistance. / Deininger, Michael W N; Druker, Brian.

In: Cancer Cell, Vol. 6, No. 2, 08.2004, p. 108-110.

Research output: Contribution to journalArticle

Deininger, Michael W N ; Druker, Brian. / SRCircumventing imatinib resistance. In: Cancer Cell. 2004 ; Vol. 6, No. 2. pp. 108-110.
@article{ed357a55cfc24e81ac25597e00cffc3c,
title = "SRCircumventing imatinib resistance",
abstract = "The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.",
author = "Deininger, {Michael W N} and Brian Druker",
year = "2004",
month = "8",
doi = "10.1016/j.ccr.2004.08.006",
language = "English (US)",
volume = "6",
pages = "108--110",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - SRCircumventing imatinib resistance

AU - Deininger, Michael W N

AU - Druker, Brian

PY - 2004/8

Y1 - 2004/8

N2 - The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.

AB - The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=5144231866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5144231866&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2004.08.006

DO - 10.1016/j.ccr.2004.08.006

M3 - Article

C2 - 15324693

AN - SCOPUS:5144231866

VL - 6

SP - 108

EP - 110

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -